Citations

Clear

6273 citation(s) found for "To, Andrew".

The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry
O’Neill, William W. , Schreiber, Theodore , Wohns, David , Rihal, Charanjit S. , Naidu, Srihari S. , Civitello, Andrew B. , Dixon, Simon , Maini, Brijeshwar , Ohman, E. Magnus , Rihal, Charanjit S. , Massaro, Joseph M.

Mayo Clinic

Journal of Interventional Cardiology | December 13, 2013 | Volume: 27 | Issue: 1 | Pages: 1-11

10.1111/joic.12080 | PMID 24329756 Get It

Abstract Objectives To evaluate the periprocedural characteristics and outcomes of patients supported with Impella 2.5 prior to percutaneous coronary intervention (pre‐PCI) versus those who received it after PCI (post‐PCI) in the setting of cardiogenic shock (CS) complicating an acute myocardial infarction (AMI). Background Early mechanical circulatory support may improve outcome in the setting of CS complicating an AMI. However, the optimal timing to initiate hemodynamic support has not been well characterized. Methods Data from 154 consecutive patients who underwent PCI and Impella 2.5 support from 38 US hospitals participating in the USpella Registry were included in our study. The primary end‐point was survival to discharge. Secondary end‐points included assessment of patients' hemodynamics and in‐hospital complications. A multivariate regression model was used to identify independent predictors for mortality. Results Both groups were comparable except for diabetes (P = 0.02), peripheral vascular disease (P = 0.008), chronic obstructive pulmonary disease (P = 0.05), and prior stroke (P = 0.04), all of which were more prevalent in the pre‐PCI group. Patients in the pre‐PCI group had more lesions (P = 0.006) and vessels (P = 0.01) treated. These patients had also significantly better survival to discharge compared to patients in the post‐PCI group (65.1% vs.40.7%, P = 0.003). Survival remained favorable for the pre‐PCI group after adjusting for potential confounding variables. Initiation of support prior to PCI with Impella 2.5 was an independent predictor of in‐hospital survival (Odds ratio 0.37, 95% confidence interval: 0.17–0.79, P = 0.01) in multivariate analysis. The incidence of in‐hospital complications included in the secondary end‐point was similar between the 2 groups. Conclusions The results of our study suggest that early initiation of hemodynamic support prior to PCI with Impella 2.5 is associated with more complete revascularization and improved survival in the setting of refractory CS complicating an AMI. (J Interven Cardiol 2014;27:1–11)
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, Lisa K. , Bering, Harriet, Carson, Kenneth R. , Kleinerman, Judith, Kukreti, Vishal , Ma, Alice , Mueller, Brigitta U., O’Brien, Sarah H. , Pasquini, Marcelo C. , Haynes, Adam E., Hicks, Lisa K. , Sarode, Ravi , Solberg, Lawrence A. , Crowther, Mark Andrew

Mayo Clinic

Hematology | December 6, 2013 | Volume: 2013 | Issue: 1 | Pages: 9-14

10.1182/asheducation-2013.1.9 | PMID 24319155 Get It

Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, Lisa K. , Bering, Harriet, Carson, Kenneth R. , Kleinerman, Judith, Kukreti, Vishal , Ma, Alice , Mueller, Brigitta U., O’Brien, Sarah H. , Pasquini, Marcelo C. , Solberg, Lawrence A. , Haynes, Adam E., Hicks, Lisa K. , Sarode, Ravi , Crowther, Mark Andrew

Mayo Clinic

Blood | December 4, 2013 | Volume: 122 | Issue: 24 | Pages: 3879-3883

10.1182/blood-2013-07-518423 | PMID 24307720 Get It

Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation
French, Anna , Suh, Jane, Roberts, Mackenna, Davies, Benjamin M. , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Rooke, Kelly, Kramm, Anneke, Judge, Andrew , Chandra, Amit , Hurley, Hannah, Grover, Liam M. , Bingham, Ian, Siegel, Bernard, Rattley, Matt S., Buckler, R. Lee, McKeon, David, Krumholz, Katie, Hook, Lilian , Rikabi, Sarah , Pigott, Rosie, Morys-Carter, Megan M. , Sabokbar, Afsie, Titus, Emily, Laâbi, Yacine, Zahkia, Raymond, Sipp, Douglas , Horne, Robert , Bravery, Christopher A., Williams, David , Wall, Ivan , Snyder, Evan Y., Barker, Richard , Bure, Kim, Reeve, Brock , Brindley, David A. , Morrey, Mark E. , May, Michael E , Lemaı̂tre, Gilles , Karp, Jeffrey M. , Carr, Andrew Jonathan , Horne, Rob

Mayo Clinic

Stem Cells and Development | December 4, 2013 | Volume: 22 | Issue: 1_suppl | Pages: 63-72

10.1089/scd.2013.0403 | PMID 24304079 Get It

Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing—of expertise and/or funding—has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
Nanoparticles for Combination Drug Therapy
Ma, Liang , Smith, Andrew M. , Kohli, Manish , Smith, A M

Mayo Clinic

ACS Nano | November 26, 2013 | Volume: 7 | Issue: 11 | Pages: 9518-9525

10.1021/nn405674m | PMID 24274814 Get It

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
Rowe, Jacob M. , Buck, Georgina , Foroni, Letizia, Gerrard, Gareth , Litzow, Mark R. , Lazarus, Hillard, Luger, Selina M. , Marks, David I. , McMillan, Andrew , Moorman, Anthony V. , Patel, Bella, Paietta, Elisabeth , Tallman, Martin S. , Goldstone, Anthony H., Fielding, Adele K.

Mayo Clinic

Blood | November 26, 2013 | Volume: 123 | Issue: 6 | Pages: 843-850

10.1182/blood-2013-09-529008 | PMID 24277073 Get It

Key Points Imatinib improves outcomes for adults with Ph+ ALL at least in part by facilitating allogeneic stem cell transplant. Allogeneic hematopoietic stem cell transplant is not dispensible in Ph+ ALL in the imatinib era.
Predictive Value of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab PCR Assay for MRSA Pneumonia
Dangerfield, Benjamin S., Chung, Andrew S. , Webb, Brandon , Seville, Maria Teresa , Chung, Andrew

Mayo Clinic

Antimicrobial Agents and Chemotherapy | November 25, 2013 | Volume: 58 | Issue: 2 | Pages: 859-864

10.1128/aac.01805-13 | PMID 24277023 Get It

ABSTRACT Pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) is associated with poor outcomes and frequently merits empirical antibiotic consideration despite its relatively low incidence. Nasal colonization with MRSA is associated with clinical MRSA infection and can be reliably detected using the nasal swab PCR assay. In this study, we evaluated the performance of the nasal swab MRSA PCR in predicting MRSA pneumonia. A retrospective cohort study was performed in a tertiary care center from January 2009 to July 2011. All patients with confirmed pneumonia who had both a nasal swab MRSA PCR test and a bacterial culture within predefined time intervals were included in the study. These data were used to calculate sensitivity, specificity, positive predictive value, and negative predictive value for clinically confirmed MRSA pneumonia. Four hundred thirty-five patients met inclusion criteria. The majority of cases were classified as either health care-associated (HCAP) (54.7%) or community-acquired (CAP) (34%) pneumonia. MRSA nasal PCR was positive in 62 (14.3%) cases. MRSA pneumonia was confirmed by culture in 25 (5.7%) cases. The MRSA PCR assay demonstrated 88.0% sensitivity and 90.1% specificity, with a positive predictive value of 35.4% and a negative predictive value of 99.2%. In patients with pneumonia, the MRSA PCR nasal swab has a poor positive predictive value but an excellent negative predictive value for MRSA pneumonia in populations with low MRSA pneumonia incidence. In cases of culture-negative pneumonia where initial empirical antibiotics include an MRSA-active agent, a negative MRSA PCR swab can be reasonably used to guide antibiotic de-escalation.
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution
Franke, Norman, Reece, Donna , Trudel, Suzanne , Chen, Christine , Delgado, Diego , Tiedemann, Rodger E. , Kukreti, Vishal , Jimenez-Zepeda, Victor Hugo , Winter, Andrew , Mıkhael, Joseph

Mayo Clinic

British Journal of Haematology | November 25, 2013 | Volume: 164 | Issue: 5 | Pages: 722-728

10.1111/bjh.12673 | PMID 24266428 Get It

SummaryAutologous stem‐cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant‐related mortality rates are high, and a recent randomized trial suggested that non‐transplant regimens produced comparable results with less toxicity. In order to define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive AL amyloidosis patients transplanted at our centre. Transplant‐related mortality occurred in 11·5%. Complete haematological response and organ response were achieved in 56% and 60%. Median overall survival was significantly lower for patients with brain‐type natriuretic peptide (BNP) >300 pg/ml (17·5 months vs. not‐reached) (P = 0·0004), troponin‐I >0·07 ng/ml (13·5 months vs. not‐reached) (P = 0·00001) and those not achieving a complete haematological response (88 months vs. not‐reached) (P = 0·0345); high BNP and troponin‐I were the most important predictive factors in a multivariate analysis. Based on this study, patients with BNP <300 pg/ml and/or normal levels of troponin‐I should be considered transplant candidates.
Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Vierkant, Robert A. , Bamlet, William R. , Lu, Karen H. , Ramus, Susan J. , Kjær, Susanne K. , Høgdall, Estrid , Høgdall, Claus , Goodman, Marc T. , García‐Closas, Montserrat , Chenevix‐Trench, Georgia , Lubiński, Jan , Nevanlinna, Heli , Olson, Sara H. , Dörk, Thilo , Giles, Graham G. , Severi, Gianluca , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Baglietto, Laura , Bogdanova, Natalia , Ekici, Arif B. , Orlow, Irene , Eccles, Diana , Hein, Alexander , Lambrechts, Diether , Jensen, Allan , Brown, Robert , Bandera, Elisa V. , Campbell, Ian , Kiemeney, Lambertus A. , Aben, Katja K.H. , Sieh, Weiva , Fogarty, Zachary C. , Levine, Douglas A. , Kupryjańczyk, Jolanta , Heitz, Florian , Flanagan, James M. , Dansonka‐Mieszkowska, Agnieszka , Menkiszak, Janusz , Pelttari, Liisa M. , Krakstad, Camilla , Trabert, Britton , Sobiczewski, Piotr , Lambrechts, Diether , Szafron, Lukasz M. , Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Trabert, B , Pelttari, L M , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Szafron, Lukasz M , Moysich, Kirsten , Orlow, Irene , Campbell, Ian G , Bamlet, William R , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Baglietto, Laura , Goodman, Marc T , Bandera, Elisa V.

Mayo Clinic

Cancer Research | November 22, 2013 | Volume: 74 | Issue: 3 | Pages: 852-861

10.1158/0008-5472.can-13-1051 | PMID 24272484 Get It

Abstract A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1α (IL1A) is both regulated by and able to activate NF-κB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-κB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76–0.93; P = 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75–0.95; P = 0.006). Considering a multiple-testing–corrected significance threshold of P &lt; 2.5 × 10−5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79–0.91; P = 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted. Cancer Res; 74(3); 852–61. ©2013 AACR.